uniQure to Participate in Upcoming Industry Conferences in October
October 03 2022 - 7:05AM
uniQure to Participate in Upcoming Industry Conferences in
October
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced its participation in the following upcoming
investor and scientific conferences:
- Chardan’s
6th Annual Genetic Medicines
Conference, October 3 – 4, 2022
- Members of uniQure’s management
team, including Ricardo Dolmetsch, Ph.D., president of research and
development, will participate in one-on-one investor meetings on
Monday, October 3.
- A fireside chat with Dr. Dolmetsch
will take place the same day from 8:30 to 8:55 a.m. ET. The live
webcast of the fireside chat can be accessed through the link
displayed in the Investors & Media section of the uniQure
website.
- European Society of Gene
& Cell Therapy (ESGCT), October 11 – 14, 2022
- uniQure will present multiple
preclinical data on its programs in temporal lobe epilepsy,
Alzheimer’s disease and amyotrophic lateral sclerosis (ALS), along
with key features of its AAV manufacturing process development.
Specific details will follow when meeting abstracts are
released.
- 2022 Latin American
Huntington’s Disease Conference, October 19 – 21, 2022
- Dr. Dolmetsch will present an
overview of uniQure’s clinical development program of AMT-130 in
Huntington’s disease on Thursday, October 20.
About uniQure
uniQure is delivering on the promise of gene
therapy – single treatments with potentially curative results. We
are leveraging our modular and validated technology platform to
rapidly advance a pipeline of proprietary gene therapies to treat
patients with hemophilia B, Huntington's disease, refractory
temporal lobe epilepsy, Fabry disease, and other
diseases. www.uniQure.com
uniQure Contacts: |
|
|
|
|
|
FOR INVESTORS: |
|
FOR MEDIA: |
|
|
|
Maria E. Cantor |
Chiara Russo |
Tom Malone |
Direct: 339-970-7536 |
Direct: 617-306-9137 |
Direct: 339-970-7558 |
Mobile: 617-680-9452 |
Mobile: 617-306-9137 |
Mobile:339-223-8541 |
m.cantor@uniQure.com |
c.russo@uniQure.com |
t.malone@uniQure.com |
Uniqure Nv (LSE:0EE0)
Historical Stock Chart
From Dec 2024 to Jan 2025
Uniqure Nv (LSE:0EE0)
Historical Stock Chart
From Jan 2024 to Jan 2025